Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14281326 | 0.92 | MEN1 (0.36) | KMT2AMEN1 | |
| SCHEMBL125570 | 0.82 | MAPT (0.41) | LMNAHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL14281322 | 0.82 | CDK2 (0.36) | KMT2AMEN1 | |
| SCHEMBL125572 | 0.71 | MAPT (0.43) | LMNAHPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL14281323 | 0.70 | TRAP1 (0.36) | KMT2AMEN1 | |
| SCHEMBL14281325 | 0.64 | MEN1 (0.36) | KMT2AMEN1 | |
| SCHEMBL25633539 | 0.61 | MEN1 (0.56) | KMT2AMEN1TACR1 | |
| SCHEMBL16604956 | 0.61 | LMNA (0.38) | FFAR4LMNATHRBTACR1IDH1 | |
| SCHEMBL3223793 | 0.61 | THRB (0.43) | HPGDKMT2AMEN1THRBALDH1A1 | |
| SCHEMBL18250112 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | INCENP, CYBA, ADCY5 | FFAR4 4070/4885LMNA 493/4885HPGD 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.